Julie Bunner, MD
Endocrinology, Diabetes & Metabolism · Wheeling, WVNPI 1013913011
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,414 and has fallen 87.5% since, to $301 in 2025.
Across 221 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$525
- Sanofi-aventis U.S. LLC$409
- Amgen$318
- Merck$283
- AstraZeneca$240
- Lilly USA, LLC$236
- plus $2K from 17 others
What the payments were for
- Food & beverage$3,51199%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $525 |
| Sanofi-aventis U.S. LLC | 31 | $409 |
| Amgen | 16 | $318 |
| Merck | 19 | $283 |
| AstraZeneca | 12 | $240 |
| Lilly USA, LLC | 22 | $236 |
| Corcept Therapeutics | 12 | $188 |
| Johnson & Johnson | 12 | $168 |
| Medtronic(2 entities) | 11 | $167 |
| Valeritas, Inc. | 10 | $155 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $143 |
| Boehringer Ingelheim | 9 | $128 |
| AbbVie | 7 | $123 |
| Mannkind Corporation | 5 | $105 |
| Averitas Pharma Inc. | 2 | $94 |
| Bayer | 1 | $75 |
| Insulet Corporation | 4 | $66 |
| Amarin Pharma, Inc. | 3 | $44 |
| Radius Health, Inc. | 2 | $28 |
| Novartis | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Antares Pharma, Inc. | 1 | $12 |
How this compares
$3,551 in reported general payments places this provider in the 70th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 154 | $235,715 |
| JardianceEmpagliflozin | 175 | $199,297 |
| MounjaroTirzepatide | 72 | $86,754 |
| JanuviaSitagliptin Phosphate | 70 | $62,094 |
| ProliaDenosumab | 32 | $54,811 |
| Tresiba Flextouch U-100Insulin Degludec | 70 | $51,845 |
| Repatha SureclickEvolocumab | 49 | $48,842 |
| FarxigaDapagliflozin Propanediol | 20 | $33,453 |
| Victoza 3-PakLiraglutide | 24 | $28,968 |
| TrulicityDulaglutide | 16 | $22,055 |
| InvokanaCanagliflozin | 15 | $21,965 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $19,103 |
| Cinacalcet Hcl | 32 | $10,997 |
| VascepaIcosapent Ethyl | 14 | $10,276 |
| TradjentaLinagliptin | 13 | $9,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $525 | $235,715154 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $128 | $215,850200 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $236 | $112,105116 claims |
| MerckJanuvia | $283 | $62,09470 claims |
| AmgenProlia | $318 | $54,81132 claims |
| AstraZenecaFarxiga | $240 | $33,45320 claims |
| Johnson & JohnsonInvokana | $168 | $21,96515 claims |
| AbbVieSynthroid | $123 | $8,471156 claims |
| Sanofi-aventis U.S. LLCLantus | $409 | $1,35611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Wheeling
- Daniel MaciasHuntington$686K
- Zachary KistkaMartinsburg$120K
- Jeremy SouleBridgeport$109K
- Philip RyanMartinsburg$35K
- John EplingBridgeport$28K
- Greta GuyerSouth Charleston$22K
- Arlene FederWeirton$20K
- Ziad KahwashSouth Charleston$17K
- Ayman ElkadryHuntington$13K
- Jessica PeriniMorgantown$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.